PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock

NEXT STORY
Fortress Biotech Announces Pricing of Series A Preferred Stock Offering
PREV STORY
Lilly and Incyte Announce Positive Top-Line Results from the North American Phase 3 Study (BREEZE-AD5) of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate- to Severe Atopic Dermatitis
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Clinically Meaningful Outcome in NIH Trial of MPC-150-IM for Heart Failure LVAD Recipients Provides Pathway for Potential Regulatory Approval

NEW YORK and MELBOURNE, Australia, Nov. 11, 2018 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ...

author_avatar
NASDAQ Market News

UroGen Pharma Reports Second Quarter 2017 Financial Results and Recent Corporate Developments

Completed Initial Public Offering Raising $66.9 Million in Gross Proceeds Continuing Enrollment of Patients ...

author_avatar
NASDAQ Market News

Roche provides update on phase III studies of etrolizumab in people with moderately to severely active ulcerative colitis

author_avatar
NASDAQ Market News